Special focus on
- Chronic Myeloid Leukemia
- Gastrointestinal Stromal Tumors
- M.D., Johns Hopkins University School of Medicine, 0 1984
- Oregon Health & Science University, 1988
- Hematology/medical oncology, Oregon Health & Science University, 1991
- American Board of Internal Medicine, (internal medicine) 1987
Dr. Heinrich specializes in medical oncology with emphasis in the development of new cancer treatments. He earned his medical degree in 1984 from Johns Hopkins School of Medicine in Baltimore. He completed both his residency training and hematology and medical oncology fellowship at OHSU. In his free time, Dr. Heinrich enjoys watching his children’s sporting activities, waterskiing and running.
Memberships and associations
- American Society of Clinical Oncology
The following clinical trials are currently accepting new participants:
- A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults with Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAF or NRAS Mutations
- A Phase 2 Study of CP-868,596 (crenolanib), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Patients with Advanced Gastrointestinal Stromal Tumors with the D842V Mutation in the PDGFRA Gene
- An Open-Label, Randomised, Multi-Centre, Phase 2 Study to Investigate the Safety and Efficacy of AT13387, either as Monotherapy or in Combination with Imatinib, in Patients with Unresectable and/or Metastatic Malignant GIST whose Tumor has Progressed Following Treatment with a Maximum of Three Tyrosine Kinase Inhibitors
- An Open-Label Expanded Access Program of Regorafenib in Patients with Gastrointestinal Stromal Tumors (GIST) After Disease Progression On or Intolerance to Imatinib and Sunitinib
- A Phase 2 Study of OSI-906 in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors
4.9 out of 5 (371 Ratings, 31 Comments)
The patient ratings score is an average of all responses to physician related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey
- Friendliness/courtesy 4.9
- Explanations about your problem/condition 4.9
- Concern shown for your questions/worries 4.8
- Effort made to include you in treatment decisions 4.9
- Used words you could understand 4.9
- Amount of time spent with you 4.8
- Your confidence in care provider 4.9
- Likelihood of recommending to others 4.9
- Likelihood of recommending to others 4.8
- Jun 03, 2018
Dr Heinrich and his support staff gives me great confidence I'm in the best possible care.
- May 30, 2018
Dr. Heinrich and his staff are always great to work with. They are limited in what they can do by the study I am on, but nothing they can work around.
- May 15, 2018
Extraordinary is how I would describe Dr. Heinrich and his staff - both clinical and lab!
- Apr 09, 2018
I am here because I trust your staff and have faith in your people to give me the very best treatment available. Yes, I would recommend you to the people that mean the most to me.
- Apr 02, 2018
he seemed nice and willing to answer questions.
- Feb 28, 2018
I very pleased to have Dr Heinrich as part of my team.
- Feb 07, 2018
Best Cancer care anywhere
- Oct 11, 2017
I'm experiencing side effects from the medications and the provider doesn't express particular concern or interest in solving or exploring the issues.
- Oct 04, 2017
I have the utmost confidence in Dr. Heinrich and his care of my cancer.
- Sep 07, 2017
life changer, life saver.